Revolutionizing Atopic Dermatitis

Experts share how this year's RAD Conference showcased cutting-edge advancements in atopic dermatitis to enhance patient care and treatment strategies.

Catch up on all updates and advancements shared at this year's Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

Discover insights from Peter Lio, MD, on precision medicine in pediatric atopic dermatitis and the promising role of ruxolitinib at the RAD 2025 Conference.

At RAD 2025, the DISCOVER trial showed that dupilumab monotherapy significantly improved moderate to severe AD symptoms in this patient population.

Galderma unveils promising long-term data on nemolizumab for atopic dermatitis, showcasing significant skin improvement and quality of life enhancements.

Discover innovative insights from the JADE REAL study on flexible dosing of abrocitinib for managing moderate to severe atopic dermatitis.

Recent research presented at the 2025 RAD Meeting explored the use of ruxolitinib cream in combination with systemic therapy.

Catch up on coverage from the final day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.

At RAD 2025, Eli Lilly revealed promising results for lebrikizumab in treating atopic dermatitis in patients with skin of color.

At RAD 2025, Tiffany Mayo, MD, emphasized the need for clinicians to recognize shared inflammatory mechanisms between AD and AA.

Data presented at the 2025 RAD Conference shows dupilumab improves daily functioning, mental health, and social aspects in patients with atopic dermatitis.

Catch up on coverage from the first day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.

A poster at RAD 2025 detailed the patient-reported outcomes across skin types and racial groups.

Co-chairs Jonathan Silverberg, MD, PhD, MPH, and Raj Chovatiya, MD, PhD, MSCI, gave insight into what attendees can look forward to at this year's meeting.

Arcutis Biotherapeutics showcases promising long-term results of Zoryve for atopic dermatitis in young children at RAD 2025, emphasizing safety and efficacy.

Discover the latest breakthroughs in atopic dermatitis treatment and expert insights from the RAD dermatology conference in Nashville.

Jonathan Silverberg, MD, PhD, MPH, walks through what to look out for in AD management.

Jonathan Silverberg, MD, PhD, MPH, talks about when and how to take itch into consideration when choosing a therapy for AD.

Jonathan Silverberg, MD, PhD, MPH, shares pearls from the ADvocate1 and 2 trials examining the use of lebrikizumab for AD.

Jonathan Silverberg, MD, PhD, MPH, talks about therapies used for AD, including nemolizumab.

Christopher Bunick, MD, PhD, discusses key differences in AD biologics and challenges in achieving optimal treatment targets.

Christopher Bunick, MD, PhD, explains why composite endpoints are now critical for evaluating patient outcomes in AD therapy.

Peter Lio, MD, discusses innovative treatments for pediatric atopic dermatitis, including microbiome therapies and botanical options.

Christopher Bunick, MD, PhD, discusses the evolving role of OX40-targeted biologics in atopic dermatitis treatment ahead of the upcoming RAD conference.

Acting upstream of cytokines may hold the key to improving biologic efficacy and itch relief in AD.

Discover cutting-edge insights on atopic dermatitis at RAD 2025, featuring expert discussions and the latest therapies to enhance your practice.

Discover how the RAD conference in Nashville enhances atopic dermatitis care, featuring expert insights and patient-focused strategies for clinicians.

Raj Chovatiya, MD, PhD, MSCI, provides insights on the clinical advantages of JAK inhibitors for atopic dermatitis.

While dietary changes can help slightly, they’re not a cure-all for most patients with AD.